



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
C014CIP/DIV2/USSERIAL NO.  
09/342,314INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Michael J. Yellin et al.FILING DATE  
June 29, 1999GROUP  
~~Not Yet Assigned~~

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1694

EXAMINER  
INITIAL

me Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)),  
"Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21,  
1999.

| Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Stopped Ongoing  
Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999.

| ~~Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241).~~

| ~~January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573  
(WO 98/30241).~~

| ~~Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240).~~

me January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482  
(WO 98/30240).

EXAMINER

Philip Gaudel 10/18/01

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.